Prosecution Insights
Last updated: October 22, 2026
Application No. 17/911,208

BIOMARKERS FOR DETECTING OF OUTCOME/RISK OF THE PATIENTS WITH A RESPIRATORY ILLNESS

Non-Final OA §112
Filed
Sep 13, 2022
Priority
Mar 13, 2020 — provisional 62/989,276 +1 more
Examiner
CHERNYSHEV, OLGA N
Art Unit
1675
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
University Health Network
OA Round
3 (Non-Final)
54%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
525 granted / 963 resolved
-5.5% vs TC avg
Strong +34% interview lift
Without
With
+34.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
63 currently pending
Career history
1014
Total Applications
across all art units

Statute-Specific Performance

§101
15.7%
-24.3% vs TC avg
§103
8.5%
-31.5% vs TC avg
§102
11.6%
-28.4% vs TC avg
§112
47.2%
+7.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 963 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Continued Examination Under 37 CFR 1.114 1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on September 15, 2026, has been entered. Response to Amendment 2. Claims 1, 25, 28, 77 and 78 have been amended and claim 52 canceled as requested in the amendment filed on September 15, 2026, 2026. Following the amendment, claims 1, 2, 9, 16, 19, 20, 23-25, 28, 49, 50 and 74-80 are pending in the instant application. 3. Claims 28, 74-78 and 80, previously withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention(s), see election made in the reply filed on September 16, 2025, are now rejoined. 4. Claims 1, 2, 9, 16, 19, 20, 23-25, 28, 49, 50 and 74-80 are under examination. 5. Any objection or rejection of record, which is not expressly repeated in this action has been overcome by Applicant’s response and withdrawn. Claim Objections 6. Claim 28 is objected to because of the following informalities: The claim recites acronyms without first providing the full name of the terms. It is suggested that the terms be spelled out at their first use and in all independent claims so that it is clearly understood what they stand for. Appropriate correction is suggested. 7. Further, claim 28, as amended, recites steps with repeated numbering, see step b) of claim 1 followed by steps a), b) to o) of claim 28. Applicant is advised to renumber the steps so that there is no uncertainty of the order. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 8. Claims 25 and 75 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. 9. Claim 25, as amended, is indefinite for reasons that follow. The claim reads, “[T]he method of claim 24, wherein the change is worsening of one or more symptoms of the respiratory illness and the patient is assessed for requirement for mechanical ventilation or mechanically ventilating the patient when the patient is determined to require mechanical ventilation.” Note that claim 25 ultimately depends from claim 1, which reads in the first step “I) determining a patient outcome risk of […] requiring mechanical ventilation,” and in the final step “II) […] mechanically ventilating the patient.” Thus, claim 25 appears recite several assessments for mechanical ventilation as well as several requirements to practice the procedure, which renders subject matter vague. 10. Claim 75 recites the limitation "inputs" in step c) of claim 28. There is insufficient antecedent basis for this limitation in the claim. Conclusion 11. Claims 1, 2, 9, 16, 19, 20, 23, 24, 49, 50, 77 and 79 are allowed. Claims 25 and 75 are rejected. Claim 28 is objected to. Claims 74, 76, 78 and 80 are objected for being dependent from objected claim. Any inquiry concerning this communication or earlier communications from the examiner should be directed to OLGA N CHERNYSHEV whose telephone number is (571)272-0870. The examiner can normally be reached 9AM to 5:30PM, Monday to Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at (571)272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /OLGA N CHERNYSHEV/ Primary Examiner, Art Unit 1675 September 30, 2026
Read full office action

Prosecution Timeline

Show 2 earlier events
Feb 23, 2026
Response Filed
Apr 16, 2026
Final Rejection mailed — §112
Jun 05, 2026
Interview Requested
Jun 16, 2026
Examiner Interview Summary
Jun 16, 2026
Applicant Interview (Telephonic)
Sep 15, 2026
Request for Continued Examination
Sep 16, 2026
Response after Non-Final Action
Oct 05, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12716893
MATERIALS AND METHODS FOR DETECTING AND TREATING AUTOIMMUNE MOVEMENT DISORDERS
4y 10m to grant Granted Aug 25, 2026
Patent 12710431
DIAGNOSTIC FOR CHILDHOOD RISK OF AUTISM SPECTRUM DISORDER
4y 10m to grant Granted Aug 18, 2026
Patent 12710433
Diagnosing a Disease Associated with Synaptic Degeneration using an Elisa for Determining a Beta-Synuclein Concentration in CSF
3y 12m to grant Granted Aug 18, 2026
Patent 12708657
PHARMACEUTICAL COMPOSITION FOR TREATING DEGENERATIVE BRAIN DISEASE, INCLUDING GLYCINE TRANSPORTER AS ACTIVE INGREDIENT
3y 10m to grant Granted Aug 18, 2026
Patent 12698344
ANTI-IDE ANTIBODIES AND USES OF SAME
4y 0m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
54%
Grant Probability
88%
With Interview (+34.0%)
2y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 963 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month